Gossamer Bio Inc (NASDAQ:GOSS) major shareholder Fund V. Gp L.P. Omega sold 82,213 shares of the stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $21.75, for a total transaction of $1,788,132.75. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
NASDAQ:GOSS traded down $0.90 on Thursday, hitting $20.70. The stock had a trading volume of 10,707 shares, compared to its average volume of 361,104. The company has a debt-to-equity ratio of 0.09, a quick ratio of 17.80 and a current ratio of 17.80. The stock has a market cap of $1.41 billion and a P/E ratio of -0.91. Gossamer Bio Inc has a 1 year low of $15.59 and a 1 year high of $25.06. The firm’s fifty day simple moving average is $19.64 and its two-hundred day simple moving average is $19.77.
Gossamer Bio (NASDAQ:GOSS) last released its earnings results on Thursday, August 8th. The company reported ($0.74) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.56) by ($0.18). Equities research analysts predict that Gossamer Bio Inc will post -2.93 EPS for the current year.
Institutional investors have recently added to or reduced their stakes in the company. Bank of Montreal Can bought a new position in shares of Gossamer Bio during the 1st quarter valued at approximately $25,000. BNP Paribas Arbitrage SA bought a new position in shares of Gossamer Bio during the 2nd quarter valued at approximately $42,000. JPMorgan Chase & Co. grew its position in shares of Gossamer Bio by 87.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 5,995 shares of the company’s stock valued at $126,000 after acquiring an additional 2,798 shares during the period. Royal Bank of Canada grew its position in shares of Gossamer Bio by 39.3% during the 2nd quarter. Royal Bank of Canada now owns 6,967 shares of the company’s stock valued at $154,000 after acquiring an additional 1,967 shares during the period. Finally, Rhumbline Advisers bought a new position in shares of Gossamer Bio during the 1st quarter valued at approximately $271,000. 54.64% of the stock is owned by hedge funds and other institutional investors.
GOSS has been the subject of several analyst reports. ValuEngine upgraded shares of Gossamer Bio from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Evercore ISI set a $30.00 price objective on shares of Gossamer Bio and gave the company a “buy” rating in a research note on Monday, August 12th. Finally, Zacks Investment Research lowered shares of Gossamer Bio from a “hold” rating to a “sell” rating in a research note on Tuesday, August 20th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company. Gossamer Bio has an average rating of “Buy” and an average price target of $28.00.
Gossamer Bio Company Profile
Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2 that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, without nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications.
Featured Story: Real Estate Investment Trust (REIT) ETF
Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.